Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an observational study to evaluate the diagnostic and prognostic value of presepsin in the critically-ill immunocompromise patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Immunocompetent sepsis patients | Sepsis patients without HIV infection (all stages), neutropenia (neutrophil count < 1 × 109/L), exposure to glucocorticoids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor. | ||
| Immunocompromised sepsis patients | Sepsis patients with HIV infection (all stages), neutropenia (neutrophil count < 1 × 109/L), exposure to glucocorticoids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor. | ||
| Patients without sepsis | Patients who admitted intensive care unit without sepsis |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of the Plasma Presepsin Concentration for Discriminating Between immunocompetent and immunocompromised patients. | For the analysis, plasma presepsin levels on Day 0 will be used. Sepsis was made on Day 7 or day of discharge. ROC-AUC of presepsin for discriminating between immunocompromised and immunocompetent patients is compared to that of procalcitonin. | up to 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| survival at ICU discharge or day 28 after enrollment | For the analysis, we will evaluate the association between presepsin and survival at ICU discharge or day 28 after enrollment | 28 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Subjects with presentation to ICU with critical illness compatible with sepsis.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jongmin Lee, M.D. | Seoul St. Mary's Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul St. Mary's Hospital | Seoul | 06591 | South Korea |
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D007153 | Immunologic Deficiency Syndromes |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood plasma, Blood serum
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D007154 | Immune System Diseases |